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SELECTION OF THE MONTH 
Big Title: Gasdermin D: A new executor in NAFLD 
 
Small Titles:  
Cirrhosis: Sarcopenia: Independent predictor of mortality in cirrhosis 
Subclinical atherosclerosis in NAFLD. 
Extended treatment experience with tenofovir alafenamide (TAF) 




Liver regeneration involves different types of liver cells, including hepatocytes and liver 
non-parenchymal cells (NPCs). However, the liver organogenetic mechanism, in 
particular the role of adult hepatocytes at ectopic sites, remains unknown. UtohI et al. 
addressed this important question using elegant mouse models with ectopic (kidney) 
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adult hepatocyte transplantation. They show that hepatocytes alone play a leading 
role as organizer cells in liver organogenesis at ectopic sites via NPC 
recruitment. 
 
ACUTE LIVER FAILURE 
Role of Msr1 and NETosis in fulminant hepatitis (FH), balancing inflammatory 
responses in virus-induced FH  
Macrophage scavenger receptor types I and II (short name: SR-A; encoded by Msr1 
in mouse) are membrane glycoproteins implicated in the pathologic deposition of 
cholesterol in arterial walls during atherogenesis. Two types of receptor subunits exist. 
These receptors mediate the endocytosis of a diverse group of macromolecules, 
including modified low density lipoproteins (LDL). SR-A is also known to be a pattern-
recognition receptor which may play a role in the maintenance of immune homeostasis. 
Msr1 is highly expressed in fetal and adult mouse livers. Moreover, MSR1 is 
overexpressed in the livers of patients with FH. This is why Tang et al. investigated the 
role of Msr1 in a mouse model of FH. Here, they reveal that Msr1 promotes virus-
induced FH by inducing activation and release of neutrophil extracellular traps 
(NETs), a process now known as NETosis, and subsequent complement 
activation. These promising results should be confirmed in human cases of FH. 
Why some patients develop acute liver failure in the course of an acute hepatitis virus 
infection is not well understood, and it is unclear to which extent virus pathogenicity or 
immunopathology drives liver damage to this stage. In order to dissect the impact of 
locally induced type I IFN responses on myeloid cell function and hepatocytes during 
acute liver inflammation, Borst et al. performed elegant infection studies with two 
different DNA viruses, vaccinia virus and murine cytomegalovirus, which both encode 
several potent type I IFN evasion proteins and efficiently infect the liver and cause 
acute hepatitis. The authors show that loss of IFN receptor leads to lack of control 
of viral infection followed by severe hepatic inflammation because Kupffer cells 
are not adequately replenished from the circulating monocyte pool. The 
observation that type I IFN is a key player in balancing inflammatory myeloid cell 
function opens new perspectives for the therapy of acute viral hepatitis. 
 
ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER DISEASE 
CAP to detect alcoholic steatosis and subclinical atherosclerosis in NAFLD 
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Controlled attenuation parameter (CAP) is a novel non-invasive measure of hepatic 
steatosis and is used along with elastrography (Fibroscan). In a study by Thiele et al., 
562 patients with biopsy-proven alcoholic liver disease were included from 4 
detoxification centers in Europe. CAP diagnosed steatosis with fair accuracy (AUC 
≥S1 = 0.77; ≥S2 = 0.78; S3 = 0.82). Importantly, CAP was superior to bright liver echo 
pattern by regular ultrasound. In the 293 patients who were admitted for detoxification, 
CAP significantly decreased after a brief period of abstinence. As expected, BMI 
predicted higher CAP, irrespective of drinking pattern. Obese patients with BMI ≥30 
kg/m2 had a significantly higher CAP, which did not decrease significantly during 
detoxification. This study demonstrates that CAP has a good diagnostic accuracy for 
diagnosing severe alcoholic liver steatosis and that the combination of obesity and 
alcoholic abuse have synergistic effects in causing steatosis. The fact that a short 
period of abstinence decreases steatosis suggest that simple steatosis is reversible 
also in alcoholic liver disease. Another important study in the field of NAFLD highlights 
the association with systemic cardiovascular problems. More specifically, a large study 
by Lee et al. investigated the association between NAFLD and subclinical 
coronary atherosclerosis. A total of 5,121 consecutive asymptomatic individuals with 
no prior history of coronary artery disease underwent abdominal ultrasonography and 
coronary computed tomography angiography (CCTA). Thirty-eight percent of the 
participants had ultrasonography- diagnosed NAFLD. After adjustment for 
cardiovascular risk factors, odds ratios for any atherosclerotic plaque and non-
calcified plaque were significantly higher in NAFLD. In addition, there was a 
significant association of fatty liver index ≥30 with non-calcified plaque and NAFLD 
fibrosis score ≥-1.455 with non-calcified plaque. This relevant large epidemiological 
study reveals that NAFLD was consistently associated with non- calcified plaque, 
suggesting an increased cardiovascular risk. These results confirm previous studies 
indicating that NAFLD is an important independent risk factor for atherosclerosis and 
cardiovascular disease. Further studies should determine whether performing CCTA 
is cost-effective in this population. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
Extended treatment experience with tenofovir alafenamide (TAF), antiviral 
treatment in HBV-associated intrahepatic cholangiocarcinoma (ICC)  
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TAF, a new prodrug of tenofovir, was recently approved by the FDA and EU to treat 
chronic HBV infection after week 48 results of two large phase III trials proved TAF as 
being comparably effective to TDF but without its potential side effects on kidney and 
bones. The interpretation of the results, however, was limited by the relatively short 
follow-up. This present week 96 findings of both international randomized double-bling 
phase III trials by Agarwal et al. confirm these earlier results. Treatment with TAF 
resulted in a similar rate of viral suppression compared to that of TDF but with a 
superior safety profile of TAF relative to TDF regarding bone and renal 
parameters. An intriguing finding was that the rate of ALT normalization was 
consistently higher for TAF than TDF, and although the mechanism of this effect 
remains yet unknown, it would be interesting to follow whether differences in the ALT 
response may influence long-term outcomes as for instance the risk of HCC 
development. 
A recent meta-analysis demonstrated a close association between the incidence of 
HBV infection and ICC occurrence, but the impact of HBV infection on outcomes 
following resection of ICC has not been reported yet. In a large cohort of 928 
consecutive Chinese patients with positive HBV surface antigen and/or HBV core 
antibody who underwent liver resection for histologically confirmed ICC Lei et al. 
examined the impact of HBV-DNA level and antiviral therapy on short- and long-term 
outcomes. Main findings were that antiviral therapy initiated either before or after 
liver resection significantly decreased tumor recurrence and prolonged long-
term survival. The positive effect of antiviral therapy on tumor recurrence was, 
however, restricted to patients with high viral load and presenting with the cholangiolar 
type ICC, a type being reported to be more closely associated with HBV infection, and 
to have a better prognosis as compared to bile duct type ICC. Preoperative antiviral 
therapy also reduced viral reactivation as well as decreased resection-related 
morbidity. The inhibitory role of preoperative antiviral therapy on postoperative viral 
reactivation also contributed to a better short- and long-term survival. This study clearly 
suggests that antiviral therapy should be considered as an integral part in the 
management of patients with resectable ICC. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
Eliminating HCV in Egypt, eight-week treatment duration revisited, patients’ 
characteristics not treatment regimen determines HCC risk after SVR 
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In this issue of the journal Elsharkawy et al. share their experience with their Egyptian 
national hepatitis treatment program, the largest HCV elimination program ever 
performed, which included a total of 337,042 patients who started treatment from 
October 2014 till end of March 2016 in specialized treatment centers. Main lessons 
learned from the national HCV elimination plan were first, that a prioritization strategy 
focused on patients with advanced disease has his limitations leading to a significant 
backlog of patients waiting for treatment; second, post-treatment follow-up is difficult 
in limited resource settings but could be increased form less than 25% to 75% over 
time, and third, cheap generic DAAs are effective reaching SVR rates of approximately 
97% and allow for expanding treatment programs in low and middle income countries. 
The Egyptian national program for treating hepatitis C can send several messages and 
share several limitations with countries of similar settings.  
Shortening DAA treatment duration to 8 weeks has shown comparable cure rates in 
clinical trials in selected treatment-naïve patients without cirrhosis as compared to the 
standard 12-week regimen. However, its effectiveness under real-world conditions 
needs further confirmation. Aim of the present study by Buggish et al. was to compare 
the effectiveness and safety of an 8 or 12 week ledipasvir plus sofosbuvir (LDV/SOF) 
containing regimen in HCV type 1-infected patients treated in the large national real-
world German Hepatitis C-Registry (DHC-R). Based on a data set of 2,404 patients, 
both the 8- and 12-week regimen achieved identical SVR rates. Relapse rates, 
however, were higher when the shorter 8-week regimen was applied to patients with 
cirrhosis, treatment experience, or HIV co-infection, emphasizing the importance of 
patient selection for the shorter treatment duration. Overall, this large study provides 
strong evidence that a shorter 8-week LDV/SOF regimen is an optimal strategy 
as long as criteria for selecting the right patients were sufficiently taken into 
account. 
Being more sick when starting antiviral therapy, might be a likely explanation for the 
reported higher frequency of hepatocellular carcinoma (HCC) occurrence in patients 
with advanced liver disease, after receipt of interferon (IFN)-free therapy for HCV 
infection as compared to the observations obtained in the interferon era. Innes and 
colleagues used data from the Scottish HCV Clinical Database to study HCC-naïve 
individuals with liver cirrhosis receiving a course of antiviral therapy in Scotland from 
1997-2016 resulting in a SVR. In univariate analysis, IFN-free receipt was indeed 
associated with a significantly increased HCC risk. However, after multivariate 
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adjustment for baseline factors like age, Child-Turcotte-Pugh score, and 
thrombocytopenia, no significant risk attributable to IFN-free therapy persisted. This 
study clearly suggests that rather a change in patient case mix, and not the use 
of IFN-free therapy per se, accounts for the higher HCC incidence seen in 
patients with cirrhosis treated with DAAs.  
 
AUTOIMMUNE HEPATITIS 
Transient elastography (TE) is useful in monitoring patients 
At present, the decision to continue, alter the dose or stop immunosuppression in 
patients with autoimmune chronic active hepatitis (AICAH) is based upon clinical, 
immunologic and biochemical parameters. Hartl et al. provide intriguing and important 
data of the potential use of TE in patients with AICAH, primary biliary cholangitis and 
primary sclerosing cholangitis. They correlated the results of biopsies with TE 
measurements and correlated these with clinical outcomes. The data showing 
that complete biochemical remission was a reliable predictor of a good 
prognosis in AIH and this is associated with fibrosis regression provides 
convincing evidence for the potential incorporation of TE measurements in the 
management of AICAH. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
LI-RADS vs. AASLD score for the non-invasive diagnosis of small HCC in high-
risk patients 
The Liver Imaging Reporting and Data System (LI-RADS) was developed by the 
American College of Radiology to standardize terminology and criteria for interpreting 
and reporting computed tomography (CT) and magnetic resonance (MR) imaging 
results of the liver in patients with a risk of HCC. The initial version of LI-RADS first 
appeared online in 2011 and has been updated several times. The aim of LI-RADS is 
to help radiologists categorize findings in at-risk populations and to assist referring 
physicians in understanding the reports of liver imaging. Observations are categorized 
from LR-1 (definitely benign) to LR-5 (definitely HCC). LI-RADS includes major and 
ancillary criteria. It has still not been determined how radiologists should use LI-RADS 
instead of AASLD criteria for the diagnosis of HCC in high-risk populations. Ronot et 
al. aimed to prospectively compare the diagnostic accuracy of AASLD and LI-RADS 
for the non-invasive diagnosis of small HCC using CT and MR imaging, and to evaluate 
7 
 
the diagnostic value of each ancillary feature of HCC found in LI-RADS. Between April 
2009 and April 2012, they enrolled patients with cirrhosis and one to three 10-30 mm 
nodules to undergo CT and MR imaging. They now report their results which show that 
the version 2014 of the LI-RADS is not more accurate than the AASLD score for 
the non-invasive diagnosis of small HCC in high-risk patients. However, they 
suggest that LI-RADS can provide important and complementary information on the 
probability of having HCC in high risk patients allowing possible changes in 
management in these patients. 
 
LIVER TRANSPLANTATION 
Severity of sarcopenia adds to the MELD score in determining the risk of death 
and metabolomics allows donor-graft matching 
Allocation of organs for liver transplantation uses the MELD score or its variations in 
many areas of the world. In recent years, there has been an increasing body of 
evidence that indicates that the severity of sarcopenia is important in the prognosis of 
cirrhotic patients. Vugt et al. performed and excellent study in over 500 from the 
European transplant registry and identified that about half of them had sarcopenia. 
Analysis of the data revealed that the presence of sarcopenia, age and hepatic 
encephalopathy were independent risk factors for mortality. Addition of 
sarcopenia to MELD score significantly improved the identification of the risk of 
mortality over 3-months compared with MELD score. With further validation, 
assessment of sarcopenia may enter routine clinical practice when attributing risk of 
mortality of cirrhotic patients. 
At present, clinical scoring systems are used to identify the likelihood of poor graft 
function following liver transplantation leading often to the use of suboptimal organs for 
transplantation, rejection of organs likely to function well after transplantation and 
inappropriate donor-recipient matching. Faitot et al. describe the results of a novel 
and exciting study where they used real-time magic-angle-spinning nuclear 
magnetic resonance (HR-MAS-NMR) metabolomic analysis of the back table 
biopsies from recipient and donors. Their results showing that the constructed 
model predicted the graft outcome with excellent accuracy. The most significant 
differences were in lactate level and phosphocholine content. With further validation 
these data will allow better use of organs and perhaps provide new targets for therapy. 
 
